Syndax Pharmaceuticals, Inc. (SNDX): Price and Financial Metrics
GET POWR RATINGS... FREE!
SNDX POWR Grades
- SNDX scores best on the Sentiment dimension, with a Sentiment rank ahead of 72% of US stocks.
- SNDX's strongest trending metric is Value; it's been moving up over the last 179 days.
- SNDX ranks lowest in Momentum; there it ranks in the 4th percentile.
SNDX Stock Summary
- The ratio of debt to operating expenses for SYNDAX PHARMACEUTICALS INC is higher than it is for about only 5.14% of US stocks.
- With a year-over-year growth in debt of -94.19%, SYNDAX PHARMACEUTICALS INC's debt growth rate surpasses just 1.17% of about US stocks.
- As for revenue growth, note that SNDX's revenue has grown 836.77% over the past 12 months; that beats the revenue growth of 98.65% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to SYNDAX PHARMACEUTICALS INC are CMRX, PSTX, BOLT, OMGA, and RXDX.
- SNDX's SEC filings can be seen here. And to visit SYNDAX PHARMACEUTICALS INC's official web site, go to www.syndax.com.
SNDX Valuation Summary
- SNDX's EV/EBIT ratio is -115; this is 1437.21% lower than that of the median Healthcare stock.
- SNDX's price/sales ratio has moved down 322.3 over the prior 82 months.
Below are key valuation metrics over time for SNDX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| SNDX | 2022-11-25 | 10.4 | 3.9 | -94.6 | -115.0 |
| SNDX | 2022-11-23 | 10.3 | 3.9 | -93.7 | -113.9 |
| SNDX | 2022-11-22 | 10.6 | 4.0 | -96.0 | -116.8 |
| SNDX | 2022-11-21 | 10.4 | 3.9 | -94.2 | -114.6 |
| SNDX | 2022-11-18 | 10.5 | 3.9 | -95.5 | -116.2 |
| SNDX | 2022-11-17 | 10.1 | 3.8 | -91.3 | -110.8 |
SNDX Growth Metrics
- The 3 year net income to common stockholders growth rate now stands at 122.48%.
- Its 4 year revenue growth rate is now at 24.26%.
- Its 3 year price growth rate is now at 91.27%.
The table below shows SNDX's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 126.576 | -10.072 | -13.946 |
| 2022-06-30 | 138.951 | -6.472 | 0.818 |
| 2022-03-31 | 139.33 | 9.789 | 15.48 |
| 2021-12-31 | 139.709 | 29.131 | 24.926 |
| 2021-09-30 | 13.512 | -87.209 | -91.695 |
| 2021-06-30 | 1.516 | -80.562 | -91.493 |
SNDX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- SNDX has a Quality Grade of D, ranking ahead of 17.57% of graded US stocks.
- SNDX's asset turnover comes in at 0.006 -- ranking 405th of 682 Pharmaceutical Products stocks.
- SYRS, LFVN, and ICPT are the stocks whose asset turnover ratios are most correlated with SNDX.
The table below shows SNDX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.006 | 1 | -0.517 |
| 2021-03-31 | 0.006 | 1 | -0.517 |
| 2020-12-31 | 0.008 | 1 | -0.570 |
| 2020-09-30 | 0.011 | 1 | -0.727 |
| 2020-06-30 | 0.014 | 1 | -0.906 |
| 2020-03-31 | 0.018 | 1 | -1.474 |
SNDX Price Target
For more insight on analysts targets of SNDX, see our SNDX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $27.67 | Average Broker Recommendation | 1.36 (Strong Buy) |
SNDX Stock Price Chart Interactive Chart >
SNDX Price/Volume Stats
| Current price | $25.07 | 52-week high | $26.51 |
| Prev. close | $25.03 | 52-week low | $13.27 |
| Day low | $24.65 | Volume | 732,800 |
| Day high | $25.27 | Avg. volume | 616,544 |
| 50-day MA | $23.18 | Dividend yield | N/A |
| 200-day MA | $19.93 | Market Cap | 1.51B |
Syndax Pharmaceuticals, Inc. (SNDX) Company Bio
Syndax Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics in oncology. The company was founded in 2005 and is based in Waltham, Massachusetts.
Latest SNDX News From Around the Web
Below are the latest news stories about SYNDAX PHARMACEUTICALS INC that investors may wish to consider to help them evaluate SNDX as an investment opportunity.
Regeneron's (REGN) Libtayo Gets EC Nod for Cervical CancerRegeneron (REGN) gets EC's approval for the label expansion of PD-1 inhibitor Libtayo for the treatment of adult patients with recurrent or metastatic cervical cancer. |
Apellis (APLS) Rises on FDA Acceptance of NDA Amendment for GAThe FDA accepts Apellis' (APLS) major amendment to the NDA for pegcetacoplan to treat geographic atrophy secondary to age-related macular degeneration. A decision is now due on Feb 26, 2023. Stock up. |
Syndax Announces Participation at Evercore ISI Annual HealthCONx ConferenceSyndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in a fireside chat at the Evercore ISI Annual HealthCONx Conference on Wednesday, November 30, 2022, at 3:30 p.m. ET. |
Gilead (GILD) Outperforms YTD: Will It Retain the Momentum?Biotech giant Gilead (GILD) outperforms the industry and the S&P 500 Index as its core business maintains momentum despite volatility. |
Bayer (BAYRY) Eylea Label Extension Gets CHMP Positive OpinionBayer (BAYRY) gets positive recommendation from the CHMP for label extension of ophthalmology drug Eylea for the treatment of preterm infants with retinopathy of prematurity. |
SNDX Price Returns
| 1-mo | 11.77% |
| 3-mo | N/A |
| 6-mo | 47.82% |
| 1-year | 55.71% |
| 3-year | 184.56% |
| 5-year | 208.36% |
| YTD | 14.53% |
| 2021 | -1.57% |
| 2020 | 153.30% |
| 2019 | 97.30% |
| 2018 | -49.20% |
| 2017 | 22.18% |
Continue Researching SNDX
Here are a few links from around the web to help you further your research on Syndax Pharmaceuticals Inc's stock as an investment opportunity:Syndax Pharmaceuticals Inc (SNDX) Stock Price | Nasdaq
Syndax Pharmaceuticals Inc (SNDX) Stock Quote, History and News - Yahoo Finance
Syndax Pharmaceuticals Inc (SNDX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...